The U.S. Senate and the U.S. House of Representatives are both considering legislation that could have a serious impact on the ability of U.S. biotechnology, drug, and medical device companies to do business with...more
3/19/2024
/ Artificial Intelligence ,
Biosimilars ,
Biotechnology ,
China ,
Department of Homeland Security (DHS) ,
Life Sciences ,
Medical Devices ,
National Security ,
OMB ,
Pharmaceutical Industry ,
Popular ,
Risk Assessment
The Rules on Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure by Public Companies (the “Cybersecurity Rules”), which the Securities and Exchange Commission (SEC) had adopted earlier this year,...more
12/22/2023
/ Chief Information Security Officer (CISO) ,
Cyber Incident Reporting ,
Cybersecurity ,
Disclosure Requirements ,
Form 8-K ,
Investment Company Act of 1940 ,
Popular ,
Publicly-Traded Companies ,
Reporting Requirements ,
Risk Management ,
Securities Act of 1933 ,
Securities and Exchange Commission (SEC)
Requirements under the proposed rules would include the disclosure of:
•Material cybersecurity incidents within four business days of the determination that a material cybersecurity incident has occurred in a Form 8-K-...more
3/22/2022
/ Corporate Governance ,
Cyber Incident Reporting ,
Cybersecurity ,
Data Breach ,
Disclosure Requirements ,
Policies and Procedures ,
Popular ,
Proposed Rules ,
Regulation S-K ,
Risk Management ,
Securities and Exchange Commission (SEC)